XORTX Therapeutics Moves Toward Phase 3 Trials to Help with an "Orphan" Kidney Disease and COVID-19 Kidney Injuries

Stock Information for XORTX Therapeutics

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About XORTX Therapeutics

XORTX Therapeutics Announces Publication of Mt. Sinai Study of Hospitalized COVID-19 Patients
XORTX Announces Research Coverage Initiated by A.G.P./Alliance Global Partners
XORTX Therapeutics Appoints Altasciences as CRO for Clinical Study
XORTX Therapeutics Announces Annual and Special Meeting of Shareholders
XORTX Therapeutics Announces Partial Exercise of Over-Allotment Option Pursuant to US Public Offering
XORTX Therapeutics Clarifies Halt of Trading in Canada and Timing for Commencement of Trading on TSX Venture Exchange
CSE Bulletin: Delist - XORTX Therapeutics Inc. (XRX)
IIROC Trading Halt - XRX

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.